What is Prometheus Biosciences?
Founded in 1995 and headquartered in San Diego, California, Prometheus Biosciences is dedicated to advancing healthcare through the development of innovative diagnostics, therapeutics, and pharmaceuticals. The company's primary focus lies in addressing unmet needs within the fields of gastrointestinal (GI) and autoimmune diseases, aiming to improve patient outcomes through targeted medical solutions.
How much funding has Prometheus Biosciences raised?
Prometheus Biosciences has raised a total of $260M across 1 funding round:
Debt
$260M
Debt (2010): $260M, investors not publicly disclosed
What's next for Prometheus Biosciences?
With substantial enterprise-level backing and a recent strategic investment, Prometheus Biosciences is poised for accelerated growth and expanded research and development initiatives. This infusion of capital is expected to fuel the advancement of its pipeline, potentially leading to new therapeutic breakthroughs and diagnostic tools for complex GI and autoimmune conditions. The company's strategic financing indicates confidence from investors in its long-term vision and market potential.
See full Prometheus Biosciences company page
